Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Olympics In China Causes Bulk-Drug Prices To Rise In India

This article was originally published in PharmAsia News

Executive Summary

The onset of the Olympics games in China already is having a fallout in India where drug makers are seeing the price of bulk drugs increasing. The Chinese government ordered several chemical firms that make the drugs to cease production temporarily to help reduce air pollution that threatens to plague the sporting events in Beijing. Even though the All India Association of Chemists and Druggists said some prices already have risen in advance of the games, the real impact is yet to be felt. Because of the rise in the price of ranitidine, aminophyline, amoxylitline and ampicillin, some of which have increased by half in the past three months, some Indian drug makers are working hard to find alternate sources. (Click here for more

You may also be interested in...

Becton Dickinson Expands Pre-Fillable Syringe Capacity, Anticipating Demand Surge

The company will invest $1.2bn over the next four years to expand and upgrade its manufacturing capacity for pre-fillable syringes and advanced drug delivery systems across seven manufacturing facilities.

CMS Cements In Place Permanent Telehealth Reimbursements In Final Physician Pay Rule

Beneficiaries in nursing homes and in rural areas will benefit from a telehealth expansion in the final CMS physician fee schedule rule.

FDA Releases COVID-19 Test Performance Data

The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts